Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31309258 | 0.80 | PDE5A (0.46) | PDE5ASCN9ASPRCRHR1ALOX5AP | |
| SCHEMBL29276218 | 0.79 | PDE2A (0.44) | PDE5ASCN9ASPRCRHR1ALOX5AP | |
| SCHEMBL30995070 | 0.79 | PDE2A (0.44) | PDE5ASCN9ASPRCRHR1ALOX5AP | |
| SCHEMBL29242949 | 0.76 | PDE5A (0.41) | PDE5ASCN9ASPRCRHR1ALOX5AP | |
| SCHEMBL31309136 | 0.76 | SCN9A (0.46) | PDE5ASCN9AALOX5APFEN1 | |
| SCHEMBL27354580 | 0.76 | SCN9A (0.46) | PDE5ASCN9AALOX5APFEN1 | |
| SCHEMBL30181352 | 0.76 | SCN9A (0.46) | PDE5ASCN9AALOX5APFEN1 | |
| SCHEMBL31235753 | 0.75 | METAP2 (0.42) | PDE5ASCN9ASPRCRHR1ALOX5AP | |
| SCHEMBL31235745 | 0.75 | METAP2 (0.42) | PDE5ASCN9ASPRCRHR1ALOX5AP | |
| SCHEMBL28934239 | 0.74 | PDE5A (0.48) | PDE5ASCN9ASPRCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409553-A1 | HETEROCYCLIC NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4433480-A1 | HETEROCYCLIC NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-09-25 | — | — | EP | disclosed |
| CN-118234730-A | Heterocyclic NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023088856-A1 | HETEROCYCLIC NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409553-A1 | HETEROCYCLIC NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | PDE5A 3097/4885SCN9A 1497/4885SPR 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.